Product Information
Registration Status: ActiveSIN15365P
FUROSEMIDE-AFT SOLUTION FOR INJECTION 50MG/5ML is approved to be sold in Singapore with effective from 2017-11-23. It is marketed by BAXTER HEALTHCARE (ASIA) PTE LTD, with the registration number of SIN15365P.
This product contains Furosemide 50mg/5ml in the form of INJECTION, SOLUTION. It is approved for INTRAVENOUS, INTRAMUSCULAR use.
This product is manufactured by Claris Injectables LTD in INDIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]
Indication
For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.
Mechanism of Action
Furosemide, a loop diuretic, inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic.
Pharmacokinetics
- Absorption
- 60% absorbed in patients with normal renal function
- Distribution
- Metabolism
- Only a small amount is hepatically metabolized to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.
- Elimination
Toxicity
Profound diuresis may cause fluid and electrolyte depletion. Excessive dehydration and potassium depletion may occur. Excessive diuresis may cause rapid weight loss, orthostatic hypotension or acute hypotensive episodes. May also cause tinnitus, reversible or permanent hearing loss or reversible deafness.
Active Ingredient/Synonyms
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid | 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid | 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid | 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid | Frusemide | Furosemid | Furosemida | Furosemide | Furosemidu | Furosemidum | Lasix (tn) | Furosemide |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.